N/A
N=14
Response of Alkylresorcinols to Different Cereals
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT01287403 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcome: Primary: Plasma Alkylresorcinol Compounds — 19357; 1548; 17307; 5385 nmol/L*h
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Refined wheat flour (Other); Esterase wholegrain wheat flour (Other); Wholegrain wheat flour (Other); Liquid whole grain wheat flour (Other); Wholegrain barley flour (Other); Liquid wholegrain barley flour (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Société des Produits Nestlé (SPN)
- Primary completion
- Aug 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Plasma Alkylresorcinol Compounds |
19357; 1548; 17307; 5385; 17139; 5634 | — |
| SECONDARY Plasma and Urinary Betaine |
— | — |
| SECONDARY Phenolic Acids |
— | — |
Summary
Cereal grains contain a wide variety of different phytochemicals which may play different roles in physiology. Their response in plasma and urine after a meal is poorly defined for most cereals. This study will investigate the plasma response and urinary excretion of cereal compounds after eating 6 different types of cereal preparation, with a focus on alkylresorcinols.
Eligibility Criteria
Inclusion Criteria
- Healthy
- Normal-overweight (BMI 19-28 kg/m2)
- Non-smokers
Exclusion Criteria
- Regular consumers of wholegrain cereals
- Allergy to cereal or milk products
Data sourced from ClinicalTrials.gov (NCT01287403). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.